The Important role of Anti-Saccharomyces cerevisiae and Anti-neutrophil cytoplasmic antibodies in diagnosis of inflammatory bowel disease
Keywords:
anti-Saccharomyces cerevisiae antibodies, inflammatory bowel disease, ulcerative colitis, Crohn’s diseaseAbstract
Background: Accurate diagnosis of inflammatory bowel disease, particularly the distinction between Crohn’s disease and ulcerative colitis, is crucial for effective treatment and prognosis. Serological markers serve as noninvasive diagnostic instruments that may assist in differentiating Crohn’s disease from ulcerative colitis, addressing cases of indeterminate colitis, and identifying specific subgroups within inflammatory bowel disease. Aim is to clarify the diagnostic precision of anti-Saccharomyces cerevisiae antibodies in relation to inflammatory bowel disease (IBD). Patients and Methods: anti-Saccharomyces cerevisiae antibodies was studied in a cohort of consecutive inflammatory bowel disease patients (Crohn’s disease and ulcerative colitis), and normal healthy as control. A standardized ELISA was performed for detection of anti-Saccharomyces cerevisiae antibodies. Results: The prevalence of anti-Saccharomyces cerevisiae antibodies was notably elevated among patients with Crohn's disease (70.9%) and ulcerative colitis (26.3%).Conclusion; Specificity of serological markers for inflammatory bowel disease is high, but low sensitivity makes them less useful as diagnostic tests.
References
Aoyama Y, Inaba T, Takahashi S, et al.: 2021. Anti-proteinase 3 antineutrophil cytoplasmic antibody reflects
disease activity and predicts the response to steroid therapy in ulcerative colitis. BMC Gastroenterol. 21:
doi: 10.1186/s12876-021-01903-5.
Cabrera-Abreu, J.C.; Davies, P.; Matek, Z.; Murphy, M.S. (2004). Performance of blood tests in diagnosis of
Inflammatory Bowel Disease in a Specialist Clinic. Arch. Dis. Child. 89: 69–71. PMCID: PMC1755933
Eggena, M., O. Cohavy, M. H. Parseghian, B. et al. 2000. Identification of histone H1 as a cognate antigen of
the ulcerative colitis-associated marker antibody pANCA. J. Autoimmun. 14:83–97. Doi.
Org./10.1006/jaut.1999.0340.
Elitsur, Y., Z. Lawrence, and N. Tolaymat. 2005. The diagnostic accuracy of serologic markers in children
with IBD: the West Virginia experience. J. Clin. Gastroentrol. 39: 670–673. doi: 10.1097/01. mcg.
78042.2d.
Forcione DG, Rosen MJ, Kisiel JB, Sands BE. 2004. Anti-Saccharomyces cerevisiae antibody (ASCA)
positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 53: 1117–22.
DOI: 10.1136/gut.2003.030734
Goldschmeding R, Schoot CE van der, Bokkel Huinink D. et al. (1989). Wegener's granulomatosis
autoantibodies identify a novel diisopropylfluorophosphate- binding protein in the lysosomes of normal
human neutrophils. J Clin Invest. 84: 1577-87. doi: 10.1172/JCI114335
Horn MP, Peter AM, Righini Grunder F, Leichtle AB, et al. (2018). PR3-ANCA and panel diagnostics in
pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn's disease. PLoS One. 13:
e0208974. https://doi.org/10.1371/journal. pone.0208974
Jaskowski, TD., Christine M. Litwin and Harry R. Hill. 2006.
Analysis of serum Antibodies in Patients Suspected of Having Inflammatory Bowel Disease. Clin. Vaccine
Immunology. 13(6): 655–60. doi: 10.1128/CVI.00034-06.
Kaul, A.; Hutfless, S.; Liu, L.; Bayless, T.M.; Marohn, M.R.; Li, X. 2012.Serum Anti-Glycan Antibody
Biomarkers for Inflammatory
Bowel Disease Diagnosis and Progression: A Systematic Review and Meta-Analysis. Inflamm. Bowel Dis.
: 1872–1884. doi: 10.1002/ibd.22862. Epub 2012 Jan 31
Kvehaugen AS, Aasbrenn M, Farup PG. 2017. Anti-Saccharomyces cerevisiae antibodies (ASCA) are
associated with body fat mass and systemic inflammation, but not with dietary yeast consumption: a crosssectional study. BMC Obes. 4: 28-32. doi: 10.1186/s40608-017-0164-2. eCollection 2017
Laass MW, Ziesmann J, de Laffolie J, Röber N, Conrad K. 2022. Anti-proteinase 3 antibodies as a biomarker
for ulcerative colitis and primary sclerosing cholangitis in children. J Pediatr Gastroenterol Nutr. 74: 463-
doi: 10.1097/MPG.0000000000003359. Epub 2021 Nov 24.
Lennard-Jones JE. (1989). Classification of IBD.Scan. J. Gastroenterol. Suppl. 70: 2-9. doi:
3109/00365528909091339.
Imakiire, S.; Takedatsu, H.; Mitsuyama, K.; et al. 2022. Role of Serum Proteinase 3 Antineutrophil
Cytoplasmic Antibodies in the Diagnosis, Evaluation of Disease Severity, and Clinical Course of Ulcerative
Colitis. Gut Liver. 16: 92–100. doi: 10.5009/gnl210211
Mokrowiecka A, Daniel P, Slomka M, Majak P, Malecka-Panas E. 2009. Clinical utility of serological
markers in inflammatory bowel disease. Hepatogastreoenterology. 56(89): 162–66. PMID: 19453050
Mizuochi T, Arai K, Kudo T, et al. 2021. Diagnostic accuracy of serum proteinase 3 antineutrophil
cytoplasmic antibodies in children with ulcerative colitis. J Gastroenterol Hepatol. 36:1538-44. doi:
1111/jgh.15296. Epub 2020 Oct 2
Mosli M, Al Beshir M, Al-Judaibi B, Al-Ameel T, Saleem A, et al. (2014). Advances in the diagnosis and
management of inflammatory bowel disease: challenges and uncertainties. Saudi J Gastroenterol. MarApr;20(2):81-101. doi: 10.4103/1319-3767.129473.
O'Morain C, Tobin A, Leen E, Suzuki Y, O'Riordan T. Criteria of
case definition in Crohn's disease and ulcerative colitis. Scand J
Gastroenterol 1989; 24:7-11. doi: 10.3109/00365528909091340
Ouadii Abakarim, Raja Hazime, Elmoumou Lahcen. 2024.
A NCA and ASCA Profiles in a Moroccan population with Inflammatory Bowel Diseases. J. Community
Hosp. Internal Med. Perspectives. 14:19-24. PMCID: PMC11259474 PMID: 39036572.
Peeters M, Joossens S, Vermeirs S, Vlietinck R, Bossuyt X, Rutgeerts P. 2001. Diagnostic value of antiSaccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disese. Am J
Gastroentol. 96:730-34. DOI: 10.1111/j.1572-0241.2001.03613.x
Renata D’Incà and Giulia Sturniolo. 2023. Biomarkers in IBD: What to Utilize for the Diagnosis.
Diagnostics. 13, 2931-42. doi.org/ 10.3390/ diagnostics13182931
Saadah O, Al-Mughales J. 2013. Serological markers of inflammatory bowel disease in children from the
Western region of Saudi Arabia. Arab J Gastroenterol. 14: 78–82. doi: 10.1016/j.ajg.2013.05.004. Epub
Sandborn WJ, Loftus EV Jr, Colombel JF, Fleming KA, Seibold F, Homburger HA, et al. 2001. Evaluation of
serologic disease marker in a population-based cohort of patients with ulcerative colitis and Crohn’s disease.
Inflamm Bowel Dis. 7:192–201. DOI: 10.1097/00054725-200108000-00003
Sastegni R, Daperno M, Ercole E, Rigazio C, Bresso F, Masoero G, et al. 2001.Detection of antiSaccharomyces cerevisiae antibodies in Crohn’s disease: is it a reliable diagnostic and prognostic marker. Dig
Liver Dis. 33: 755–61. DOI: 10.1016/s1590-8658(01)80692-7
Takedatsu, H.; Mitsuyama, K.; Fukunaga, S.; et al. (2018). Diagnostic and Clinical Role of Serum Proteinase
Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Disease: Serologic Markers of Ulcerative
Colitis. J. Gastroenterol. Hepatol. 33: 1603–07.
https:// doi.org/10.1111/jgh. 14140
Torres J, Petralia F, Sato T, et al.: 2020. Serum biomarkers identify patients who will develop inflammatory
bowel diseases up to 5 years before diagnosis. Gastroenterology. 2020; 159: 96-104. doi: 10.1053/ j.gastro.
03.007. Epub 2020 Mar 9.
Xu Y, Xu F, Li W, et al. 2020. The diagnostic role and clinical association of serum proteinase 3 antineutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease. Scand J
Gastroenterol. 2020, 55: 806 -13. doi: 10.1080/00365521. 2020. 1781926. Epub 2020 Jun 22.
